Generic placeholder image

Current Drug Metabolism

Editor-in-Chief

ISSN (Print): 1389-2002
ISSN (Online): 1875-5453

Research Article

Development and Validation of a Sensitive UPLC-Q-TOF-MS/MS for the Measurement of Nine Components in Rat Plasma and Tissues and its Application to Pharmacokinetics and Tissue Distribution Studies with Xuanfei Baidu Granules

Author(s): Xinrui Wang, Shuai Quan, Han Zhang, Xinbo Song, Jingze Zhang* and Dailin Liu*

Volume 23, Issue 2, 2022

Published on: 08 March, 2022

Page: [150 - 163] Pages: 14

DOI: 10.2174/1389200223666220215151245

Price: $65

Abstract

Background: Xuanfei Baidu granules (XFBD granules) are based on the prescription of Xuanfei Baidu, which showed promise as a first-line treatment against Corona Virus Disease 2019 (COVID-19) in Wuhan, Hubei. On March 2, 2021, XFBD granules were marketed as a novel drug for epidemic diseases. However, there is little information about the pharmacokinetics and tissue distribution of the main constituents in XFBD granules.

Methods: A sensitive analytical method was developed for detecting the marker components of XFBD granules by ultra-high performance liquid chromatography with quadrupole time-of-flight mass spectrometry (UPLC-Q-TOFMS/ MS), and for studying its pharmacokinetics and tissue distribution by UPLC-QDa.

Results: Following an oral administration of a single granule in experimental rats at a dose of 14 g/kg for pharmacokinetic and tissue distribution studies, 42 compounds and nine analytes were identified in XFBD granules. Nine compounds were detected in the lungs and the liver of the rats. Six compounds were detected in the kidneys. Five compounds were detected in the spleen and three were detected in the heart. As it went undetected in the brain, XFBD granules are considered unable to cross the blood-brain barrier.

Conclusion: A sensitive UPLC-Q-TOF-MS/MS method was established and validated for the quantification of nine components in rat plasma and tissue samples. This method was successfully applied to study the pharmacokinetics and tissue distribution profiles of XFBD granules after their oral administration.

Keywords: Xuanfei Baidu Granules, chemical components, pharmacokinetics, tissue distribution, UPLC-Q-TOF-MS/MS method, COVID-19.

Graphical Abstract
[1]
Ren, J.L.; Zhang, A.H.; Wang, X.J. Traditional Chinese medicine for COVID-19 treatment. Pharmacol. Res., 2020, 155, 104743.
[http://dx.doi.org/10.1016/j.phrs.2020.104743] [PMID: 32145402 ]
[2]
Guo, D.A.; Liu, C.X. Rudolf Bauer: China anti-COVID-19 success is closely related with the role TCM played. Chin. Herb. Med., 2020, 12(4), 347-348.
[http://dx.doi.org/10.1016/j.chmed.2020.09.001] [PMID: 32929323 ]
[3]
Wang, Y.; Li, X.; Zhang, J.H.; Xue, R.; Qian, J.Y.; Zhang, X.H.; Zhang, H.; Liu, Q.Q.; Fan, X.H.; Cheng, Y.Y.; Zhang, B.L. Mechanism of Xuanfei Baidu Tang in treatment of COVID-19 based on network pharmacology. Zhongguo Zhongyao Zazhi, 2020, 45(10), 2249-2256.
[PMID: 32495577 ]
[4]
Yue, X.; Lu, L.; Liu, H.; Xue, H. Pharmacokinetics, bioavailability and metabolism of cligosiban, an antagonist of oxytocin receptor, in rat by liquid chromatography hyphenated with electrospray ionization tandem mass spectrometry. J. Pharm. Biomed. Anal., 2019, 164, 725-733.
[http://dx.doi.org/10.1016/j.jpba.2018.11.045] [PMID: 30472591 ]
[5]
Niu, W.H.; Wu, F.; Cao, W.Y.; Wu, Z.G.; Chao, Y.C.; Liang, C. Network pharmacology for the identification of phytochemicals in traditional Chinese medicine for COVID-19 that may regulate interleukin- 6. Biosci. Rep., 2021, 41(1), 41.
[http://dx.doi.org/10.1042/BSR20202583] [PMID: 33146673 ]
[6]
Deng, J.G.; Hou, X.T.; Zhang, T.J.; Bai, G.; Hao, E.W.; Chu, J.J.H.; Wattanathorn, J.; Sirisa-Ard, P.; Soo Ee, C.; Low, J.; Liu, C.X. Carry forward advantages of traditional medicines in prevention and control of outbreak of COVID-19 pandemic. Chin. Herb. Med., 2020, 12(3), 207-213.
[http://dx.doi.org/10.1016/j.chmed.2020.05.003] [PMID: 32834811 ]
[7]
Shi, Y.; Wang, G.; Cai, X.P.; Deng, J.W.; Zheng, L.; Zhu, H.H.; Zheng, M.; Yang, B.; Chen, Z. An overview of COVID-19. J. Zhejiang Univ. Sci. B, 2020, 21(5), 343-360.
[http://dx.doi.org/10.1631/jzus.B2000083] [PMID: 32425000 ]
[8]
Lai, C.C.; Liu, Y.H.; Wang, C.Y.; Wang, Y.H.; Hsueh, S.C.; Yen, M.Y.; Ko, W.C.; Hsueh, P.R. Asymptomatic carrier state, acute respiratory disease, and pneumonia due to severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2): Facts and myths. J. Microbiol. Immunol. Infect., 2020, 53(3), 404-412.
[http://dx.doi.org/10.1016/j.jmii.2020.02.012] [PMID: 32173241 ]
[9]
Meo, S.A.; Alhowikan, A.M.; Al-Khlaiwi, T.; Meo, I.M.; Halepoto, D.M.; Iqbal, M.; Usmani, A.M.; Hajjar, W.; Ahmed, N. Novel coronavirus 2019-nCoV: Prevalence, biological and clinical characteristics comparison with SARS-CoV and MERS-CoV. Eur. Rev. Med. Pharmacol. Sci., 2020, 24(4), 2012-2019.
[PMID: 32141570 ]
[10]
Lin, S.P.; Chu, P.M.; Tsai, S.Y.; Wu, M.H.; Hou, Y.C. Pharmacokinetics and tissue distribution of resveratrol, emodin and their metabolites after intake of Polygonum cuspidatum in rats. J. Ethnopharmacol., 2012, 144(3), 671-676.
[http://dx.doi.org/10.1016/j.jep.2012.10.009] [PMID: 23069945 ]
[11]
Dong, X.; Fu, J.; Yin, X.; Cao, S.; Li, X.; Lin, L.; Ni, J. Emodin: A review of its pharmacology, toxicity and pharmacokinetics. Phytother. Res., 2016, 30(8), 1207-1218.
[http://dx.doi.org/10.1002/ptr.5631] [PMID: 27188216 ]
[12]
Huang, P.; Tang, Y.; Li, C.; Zhou, H.; Yu, L.; Wan, H.; He, Y. Correlation study between the pharmacokinetics of seven main active ingredients of Mahuang decoction and its pharmacodynamics in asthmatic rats. J. Pharm. Biomed. Anal., 2020, 183, 113144.
[http://dx.doi.org/10.1016/j.jpba.2020.113144] [PMID: 32070931 ]
[13]
Wu, Z.; Kong, X.; Zhang, T.; Ye, J.; Fang, Z.; Yang, X. Pseudoephedrine/ephedrine shows potent anti-inflammatory activity against TNF-α- mediated acute liver failure induced by lipopolysaccharide/Dgalactosamine. Eur. J. Pharmacol., 2014, 724, 112-121.
[http://dx.doi.org/10.1016/j.ejphar.2013.11.032] [PMID: 24365491 ]
[14]
Wang, J.W.; Chiang, M.H.; Lu, C.M.; Tsai, T.H. Determination the active compounds of herbal preparation by UHPLC-MS/MS and its application on the preclinical pharmacokinetics of pure ephedrine, single herbal extract of Ephedra, and a multiple herbal preparation in rats. J. Chromatogr. B Analyt. Technol. Biomed. Life Sci., 2016, 1026, 152-161.
[http://dx.doi.org/10.1016/j.jchromb.2015.12.027] [PMID: 26724253 ]
[15]
Zeng, X.; Su, W.; Liu, B.; Chai, L.; Shi, R.; Yao, H. A review on the pharmacokinetic properties of naringin and its therapeutic efficacies in respiratory diseases. Mini Rev. Med. Chem., 2020, 20(4), 286-293.
[http://dx.doi.org/10.2174/1389557519666191009162641] [PMID: 32134369 ]
[16]
Khodayar, M.J.; Kalantari, H.; Mahdavinia, M.; Khorsandi, L.; Alboghobeish, S.; Samimi, A.; Alizadeh, S.; Zeidooni, L. Protective effect of naringin against BPA-induced cardiotoxicity through prevention of oxidative stress in male Wistar rats. Drug Chem. Toxicol., 2020, 43(1), 85-95.
[http://dx.doi.org/10.1080/01480545.2018.1504958] [PMID: 30264589 ]
[17]
Ben-Azu, B.; Nwoke, E.E.; Aderibigbe, A.O.; Omogbiya, I.A.; Ajayi, A.M.; Olonode, E.T.; Umukoro, S.; Iwalewa, E.O. Possible neuroprotective mechanisms of action involved in the neurobehavioral property of naringin in mice. Biomed. Pharmacother., 2019, 109, 536-546.
[http://dx.doi.org/10.1016/j.biopha.2018.10.055] [PMID: 30399589 ]
[18]
Kaur, G.; Prakash, A. Involvement of the nitric oxide signaling in modulation of naringin against intranasal manganese and intracerbroventricular β-amyloid induced neurotoxicity in rats. J. Nutr. Biochem., 2020, 76, 108255.
[http://dx.doi.org/10.1016/j.jnutbio.2019.108255] [PMID: 31759198 ]
[19]
Zeng, X.; Su, W.; Zheng, Y.; He, Y.; He, Y.; Rao, H.; Peng, W.; Yao, H. Pharmacokinetics, tissue distribution, metabolism, and excretion of naringin in aged rats. Front. Pharmacol., 2019, 10, 34.
[http://dx.doi.org/10.3389/fphar.2019.00034] [PMID: 30761003 ]
[20]
Zou, W.; Yang, C.; Liu, M.; Su, W. Tissue distribution study of naringin in rats by liquid chromatography-tandem mass spectrometry. Arzneimittelforschung, 2012, 62(4), 181-186.
[http://dx.doi.org/10.1055/s-0031-1299746] [PMID: 22270844 ]
[21]
Zeng, X.; Yao, H.; Zheng, Y.; He, Y.; He, Y.; Rao, H.; Li, P.; Su, W. Tissue distribution of naringin and derived metabolites in rats after a single oral administration. J. Chromatogr. B Analyt. Technol. Biomed. Life Sci., 2020, 1136, 121846.
[http://dx.doi.org/10.1016/j.jchromb.2019.121846] [PMID: 31821965 ]
[22]
Gong, H.L.; Tang, W.F.; Wang, J.; Chen, G.Y.; Huang, X. Effect of formula compatibility on the pharmacokinetics of components from Dachengqi Decoction in rats. Chin. J. Integr. Med., 2012, 18(9), 708-713.
[http://dx.doi.org/10.1007/s11655-012-1205-9] [PMID: 22936325 ]
[23]
Fouladi, S.; Masjedi, M.; Ganjalikhani Hakemi, M.; Eskandari, N. The review of in vitro and in vivo studies over the glycyrrhizic acid as natural remedy option for treatment of allergic asthma. Iran. J. Allergy Asthma Immunol., 2019, 18(1), 1-11.
[http://dx.doi.org/10.18502/ijaai.v18i1.626] [PMID: 30848569]
[24]
Yu, J.Y.; Ha, J.Y.; Kim, K.M.; Jung, Y.S.; Jung, J.C.; Oh, S. Anti- Inflammatory activities of licorice extract and its active compounds, glycyrrhizic acid, liquiritin and liquiritigenin, in BV2 cells and mice liver. Molecules, 2015, 20(7), 13041-13054.
[http://dx.doi.org/10.3390/molecules200713041] [PMID: 26205049 ]
[25]
Richard, S.A. Exploring the pivotal immunomodulatory and antiinflammatory potentials of glycyrrhizic and glycyrrhetinic acids. Mediators Inflamm., 2021, 2021, 6699560.
[http://dx.doi.org/10.1155/2021/6699560] [PMID: 33505216 ]
[26]
Han, Y.J.; Kang, B.; Yang, E.J.; Choi, M.K.; Song, I.S. Simultaneous determination and pharmacokinetic characterization of glycyrrhizin, isoliquiritigenin, liquiritigenin, and liquiritin in rat plasma following oral administration of glycyrrhizae radix extract. Molecules, 2019, 24(9), 24.
[http://dx.doi.org/10.3390/molecules24091816] [PMID: 31083444]

Rights & Permissions Print Cite
© 2024 Bentham Science Publishers | Privacy Policy